<DOC>
	<DOCNO>NCT00004253</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Specialized radiation therapy delivers high dose radiation directly tumor may kill tumor cell cause less damage normal tissue . PURPOSE : Phase II trial study effectiveness combination chemotherapy specialize high-dose radiation therapy treat patient stage II stage III non-small cell lung cancer remove surgery .</brief_summary>
	<brief_title>Combination Chemotherapy Radiation Therapy Treating Patients With Stage II Stage III Non-small Cell Lung Cancer That Can Be Removed By Surgery</brief_title>
	<detailed_description>OBJECTIVES : - Determine probability overall survival local control patient favorable prognosis , unresectable stage II-IIIA/B non-small cell lung cancer receive paclitaxel carboplatin plus 3-D conformal hyperfractionation radiotherapy ( 3D-CHRT ) . - Determine incidence severity nonhematologic toxicity , specifically esophagitis pneumonitis , 3D-CHRT chemotherapy paclitaxel carboplatin patient . - Correlate complication rate radiation base effective dose determine safe treatment guideline . - Determine feasibility patient-specific dose escalation use regimen patient . - Determine quality life symptom distress patient regimen . OUTLINE : This dose-escalation study 3-D conformal hyperfractionated radiotherapy ( 3D-CHRT ) . Patients receive paclitaxel IV 1 hour follow immediately carboplatin IV 30 minute weekly 6-8 week . Patients undergo 3D-CHRT twice daily five day week 6-8 week . Cohorts patient receive escalate dos 3D-CHRT 4 dose level . Quality life assess prior study , weekly chemotherapy radiotherapy , 3 6 month . Patients follow 6 week , every 3 month 1 year , every 6 month 2 year annually thereafter . PROJECTED ACCRUAL : A total 26-72 patient accrue study within 3 year .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Patients unresected locally advanced nonsmall cell lung cancer Stage II , IIIA , IIIB No evidence hematogenous metastases No pleural effusion ( ) chest xray ( except thoracotomy invasive thoracic procedure ) No intrathoracic tumor recurrence follow resection PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 70100 % Life expectancy : Not specify Hematopoietic : Absolute granulocyte count least 2,000/mm3 Platelet count least 130,000/mm3 Hemoglobin least 10 g/dL Hepatic : Bilirubin great 1.5 mg/dL SGOT great 1.5 time upper limit normal ( unless cause documented benign disease ) Renal : Creatinine great 1.5 mg/dL Cardiovascular : No active symptomatic cardiac disease No acute myocardial infarction within past 6 month No angina No congestive heart failure No uncontrolled arrhythmias Cardiac ejection fraction great 50 % Pulmonary : FEV1 least 1.25 L AND DLCO least 50 % predict Other : Not pregnant Fertile patient must use effective contraception Weight loss great 5 % within 3 month diagnosis No prior malignancy within past 3 year except nonmelanomatous skin cancer PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy Endocrine therapy : Not specify Radiotherapy : No prior thoracic neck radiotherapy Surgery : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2002</verification_date>
	<keyword>stage II non-small cell lung cancer</keyword>
	<keyword>stage IIIA non-small cell lung cancer</keyword>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
</DOC>